Abdelgalil, A. (2023). Potential Deleterious Effects Following the First Dose of Medroxyprogesterone Acetate as a Contraceptive in Cats. Journal of Applied Veterinary Sciences, 8(4), 1-5. doi: 10.21608/javs.2023.207698.1223
Ahmed I. Abdelgalil. "Potential Deleterious Effects Following the First Dose of Medroxyprogesterone Acetate as a Contraceptive in Cats". Journal of Applied Veterinary Sciences, 8, 4, 2023, 1-5. doi: 10.21608/javs.2023.207698.1223
Abdelgalil, A. (2023). 'Potential Deleterious Effects Following the First Dose of Medroxyprogesterone Acetate as a Contraceptive in Cats', Journal of Applied Veterinary Sciences, 8(4), pp. 1-5. doi: 10.21608/javs.2023.207698.1223
Abdelgalil, A. Potential Deleterious Effects Following the First Dose of Medroxyprogesterone Acetate as a Contraceptive in Cats. Journal of Applied Veterinary Sciences, 2023; 8(4): 1-5. doi: 10.21608/javs.2023.207698.1223
Potential Deleterious Effects Following the First Dose of Medroxyprogesterone Acetate as a Contraceptive in Cats
Department of Surgery, Anesthesiology and Radiology- Faculty of Veterinary Medicine - Cairo University, Giza, Egypt
Receive Date: 28 April 2023,
Revise Date: 04 June 2023,
Accept Date: 27 July 2023
Abstract
The aim of the present work was to investigate the deleterious effects of the first dose of medroxyprogesterone acetate (MPA) on the female genital system of cats. The study was conducted on 315 cats of different breeds who received their first dose (75 mg) of MPA as a contraceptive. Complete animal identification and stage of estrus were documented at admission. Physical, radiographic and ultrasonographic examinations were done on cats that expressed deleterious manifestations. All of the presented cats received an overdose of MPA during the estrous phase of the estrous cycle. Out of 315 cats who received their first dose of MPA, 27 (8.6 %) demonstrated varied deleterious effects related to the female genital system. Deleterious effects were reported within 15–90 days, including pyometra (n=10, 37.0%), endometritis (n=8, 29.6%), mammary gland hyperplasia (n=4, 14.8 %), cystic endometrial hyperplasia (n=3, 11.2%) and ovarian cyst (n=2, 7.4%). The incidence of these adverse effects increased with age. Persian cats seem to be more susceptible than other cat breeds. Long haired cat breeds seem to be more susceptible to adverse effects following injection of exogenous progestins (MPA) than short haired breeds (Siamese and Egyptian mau). Deleterious effects of MPA occurred following the first overdose. It is advised to use MPA as a contraceptive in the recommended dose during the inter-estrous or anestrous phase.
DE BOSSCHERE, H., DUCATELLE, R., VERMEIRSCH, H., SIMOENS, P., and CORYN, M., 2002. Estrogen-α and progesterone receptor expression in cystic endometrial hyperplasia and pyometra in the bitch. Animal Reproduction Science, 15; 70: 251-259. https://doi.org/10.1016/S0378-4320(02)00013-1
DE COCK, H., DUCATELLE, R., TILMANT, K., and DE SCHEPPER, J., 2002. Possible role for insulin like growth factor-I in the pathogenesis of cystic endometrial hyperplasia pyometra complex in the bitch. Theriogenology, 57: 2271-2287. https://doi.org/10.1016/s0093-691x(02)00856-7
JACOBS, T.M., HOPPE, B.R., POEHLMANN, C.E., FERRACONE, J.D., and SORENMO, K.U., 2010. Mammary adenocarcinomas in three male cats exposed to medroxyprogesterone acetate (1990- 2006). Journal of Feline Medicine and Surgery, 12: 169-174. https://doi.org/10.1016/j.jfms.2009.08.004
JOHNSTON, S.D., ROOT KUSTRITZ, M.V., and OLSON, P.N.S., 2001. Prevention and termination of feline pregnancy. In Johnston, SD, Root Kustritz, MV, Olson, PNS (Eds.). Canine and Feline Theriogenology, Philadelphia, USA: WB Saunders. pp. 447-452.
KESKIN, A., YILMAZBAS, G., YILMAZ, R., OZYIGIT, M., and GUMEN, A., 2009. Pathological abnormalities after long-term administration of medroxyprogesterone acetate in a queen. Journal of Feline Medicine and Surgery, 11: 518521. https://doi.org/10.1016/j.jfms.2008.10.006
KIM, K.S., and KIM, O., 2005. Cystic endometrial hyperplasia and endometritis in a dog following prolonged treatment of medroxyprogesterone acetate. Journal of Veterinary Science, 6: 81-82. http://dx.doi.org/10.4142/jvs.2005.6.1.81
LORETTI, A.P., ILHA, M.R., ORDAS, J., LAS, D.E., and MULAS, J.M., 2005. Clinical, pathological and immunohistochemical study of feline mammary fibroepithelial hyperplasia following a single injection of depot medroxyprogesterone acetate. Journal of Feline Medicine and Surgery, 7: 43-52. https://doi.org/10.1016/j.jfms.2004.05.002
MAX, A., JURKA, P., DOBRZYŃSKI, A., and RIJSSELAERE, T., 2015. Non-surgical contraception in female dogs and cats. Acta Scientiarum Polonorum Zootechnica, 14: 3-18.
OCHOTA, M., NOWAK, M., DZIECIOL, M., and NIZANSKI, W., 2014. Mammary adenocarcinoma after 10-year medroxyprogesterone acetate supplementation in an ovariectomized cat. Pakistan Veterinary Journal, 34: 406-409. http://www.pvj.com.pk/pdf-files/34_3/406-409.pdf
ROMAGNOLI, S. 2002. Clinical use of hormones in the control of reproduction in bitches and queens. Proceedings of the Veterinary Sciences Congress (SPCV), Oeiras, Portugal. pp. 162-166.
ROMAGNOLI, S. 2006. Control of Reproduction in Dogs and Cats: Use and Misuse of Hormones.The 31st Congress of the World Small Animal Veterinary Association World Congress Proceedings,Prague, Czech Republic.
ROMAGNOLI, S. 2015. Progestins to control feline reproduction: Historical abuse of high doses and potentially safe use of low doses. Journal of Feline Medicine and Surgery, 17(9):743-52. doi: 10.1177/1098612X15594987. https://doi.org/10.1177/1098612x15594987
SKORUPSKI, K.A., OVERLEY, B., SHOFER, F.S., GOLDSCHMIDT, M.H., MILLER, C.A., and SORENMO, K.U., 2005. Clinical characteristics of mammary carcinoma in male cats. Journal of Veterinary Internal Medicine, 19: 52-55. https://doi.org/10.1892/0891-6640(2005)19%3C52:ccomci%3E2.0.co;2
SPARKES, A.H., ROGERS, K., and HENLEY, W.E.,2006. A questionnaire-based study of gestation, parturition and neonatal mortality in pedigree breeding cats in the UK. J Feline Med Surg., 8:145. https://doi.org/10.1016/j.jfms.2005.10.003